FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of Novexel

Novexel to be acquired by AstraZeneca

04-Jan-2010 - Novexel announced that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing. The transaction is expected to close ...

Novexel Starts Phase II Clinical Trial with NXL103 in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

10-Nov-2009 - Novexel announced that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral ...

antibiotics clinical trials USA

Novexel Strengthens its Scientific Advisory Board with the Appointment of Dr. Karen Bush

30-Mar-2009 - Novexel announced the appointment of Dr. Karen Bush to the Company’s Scientific Advisory Board (SAB). Novexel’s SAB is chaired by Dr. David Shlaes who sits on the Company’s board. Dr. Bush, who is currently Adjunct Professor at the Department of Biology at Indiana University, brings extensive ...

anti-infectives antibiotics biochemistry +4

Novexel’s NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial

04-Mar-2009 - Novexe announced that its most advanced injectable antibacterial, which combines Novexel’s broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered a second Phase II clinical trial. This Phase II trial with NXL104/ceftazidime ...

antibiotics bacteria clinical trials +1

Novexel’s NXL104/ceftazidime Combination Commences Phase II Clinical Trial

14-Nov-2008 - Novexe announced that its most advanced injectable antibacterial, which combines Novexel’s broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered Phase II clinical trials. The initial Phase II trial with NXL104/ceftazidime ...

antibiotics bacteria ciprofloxacin +3

Novexel Reports Positive Phase II Trial Results with NXL103 in Adult Patients with Community Acquired Pneumonia

24-Oct-2008 - Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announced positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community ...

antibiotics clinical trials community-acquired pneumonia +1